Agilent Technologies, Inc. $A Shares Sold by Checchi Capital Advisers LLC

Checchi Capital Advisers LLC lessened its position in shares of Agilent Technologies, Inc. (NYSE:A) by 5.1% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,395 shares of the medical research company’s stock after selling 128 shares during the quarter. Checchi Capital Advisers LLC’s holdings in Agilent Technologies were worth $283,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. raised its stake in Agilent Technologies by 13.5% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company’s stock valued at $4,279,000 after purchasing an additional 4,362 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in Agilent Technologies by 8.3% in the 1st quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company’s stock valued at $3,606,000 after purchasing an additional 2,371 shares during the last quarter. Alps Advisors Inc. raised its stake in Agilent Technologies by 29.5% in the 1st quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company’s stock valued at $1,563,000 after purchasing an additional 3,040 shares during the last quarter. D.A. Davidson & CO. raised its stake in Agilent Technologies by 30.4% in the 1st quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company’s stock valued at $1,108,000 after purchasing an additional 2,207 shares during the last quarter. Finally, LGT Capital Partners LTD. raised its stake in Agilent Technologies by 7.6% in the 1st quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company’s stock valued at $89,870,000 after purchasing an additional 54,302 shares during the last quarter.

Agilent Technologies Trading Down 2.2%

NYSE A opened at $138.56 on Wednesday. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71. Agilent Technologies, Inc. has a 12 month low of $96.43 and a 12 month high of $153.84. The company has a market cap of $39.28 billion, a P/E ratio of 32.53, a P/E/G ratio of 4.62 and a beta of 1.26. The company has a 50-day moving average of $123.61 and a 200-day moving average of $116.64.

Agilent Technologies (NYSE:A) last issued its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.37. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The business had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.67 billion. During the same quarter in the previous year, the business earned $1.32 EPS. The company’s revenue for the quarter was up 10.1% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, equities analysts predict that Agilent Technologies, Inc. will post 5.58 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 22nd. Stockholders of record on Tuesday, September 30th will be issued a dividend of $0.248 per share. The ex-dividend date is Tuesday, September 30th. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.7%. Agilent Technologies’s payout ratio is presently 23.24%.

Wall Street Analysts Forecast Growth

A has been the subject of several analyst reports. Wall Street Zen raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Friday, October 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of Agilent Technologies in a research note on Saturday, September 27th. Barclays boosted their target price on shares of Agilent Technologies from $125.00 to $150.00 and gave the company an “equal weight” rating in a research note on Thursday, October 2nd. Evercore ISI upped their price objective on shares of Agilent Technologies from $128.00 to $140.00 and gave the company an “in-line” rating in a research note on Tuesday. Finally, Robert W. Baird upped their price objective on shares of Agilent Technologies from $141.00 to $142.00 and gave the company an “outperform” rating in a research note on Thursday, August 28th. Six equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $143.17.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.